The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 |
doi: 10.3389/fimmu.2024.1434300
This article is part of the Research Topic Immunological Precision Therapeutics: Integrating Multi-Omics Technologies and Comprehensive Approaches for Personalized Immune Intervention View all 12 articles
IGFBP7+ Subpopulation and IGFBP7 Risk Score in Astrocytoma: Insights from scRNA-Seq and Bulk RNA-Seq
Provisionally accepted
Liang Zhao
1*
Wenwen Shao
2
Xiahou Zhikai
3
Li Ren
1
Chaobo Liu
1*
Yanbing Song
1*
Hao Xu
1*
Zhihan Wang
1
Jin Xing
1*- 1 Shanghai Pudong Hospital, Shanghai, Shanghai Municipality, China
- 2 Shandong University of Traditional Chinese Medicine, Jinan, China
- 3 Beijing Sport University, Beijing, Beijing Municipality, China
Background: Glioma is the predominant malignant brain tumor that lacks effective treatment options due to its shielding by the blood-brain barrier (BBB). Astrocytes play a role in the development of glioma, yet the diverse cellular composition of astrocytoma has not been thoroughly researched.We examined the internal diversity of seven distinct astrocytoma subgroups through single-cell RNA sequencing (scRNA-seq), pinpointed crucial subgroups using CytoTRACE, monocle2 pseudotime analysis, and slingshot pseudotime analysis, employed various techniques to identify critical subgroups, and delved into cellular communication analysis. Then, we combined the clinical information of GBM patients and used bulk RNA sequencing (bulk RNA-seq) to analyze the prognostic impact of the relevant molecules on GBM patients, and we performed in vitro experiments for validation.The analysis of the current study revealed that C0 IGFBP7+ Glioma cells were a noteworthy subpopulation of astrocytoma, influencing the differentiation and progression of astrocytoma. A predictive model was developed to categorize patients into high-and low-scoring groups based on the IGFBP7 Risk Score (IGRS), with survival analysis revealing a poorer prognosis for the high-IGRS group. Analysis of immune cell infiltration, identification of genes with differential expression, various enrichment analyses, assessment of copy number variations, and evaluation of drug susceptibility were conducted, all of which highlighted their significant influence on the prognosis of astrocytoma.This research enhances comprehension of the diverse cell composition of astrocytoma, delves into the various factors impacting the prognosis of astrocytoma, and offers fresh perspectives on treating glioma.
Keywords: Astrocytoma, single-cell, Bulk RNA-seq, C0 IGFBP7+ Glioma cells, prognosis
Received: 17 May 2024; Accepted: 09 Sep 2024.
Copyright: © 2024 Zhao, Shao, Zhikai, Ren, Liu, Song, Xu, Wang and Xing. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Liang Zhao, Shanghai Pudong Hospital, Shanghai, 200032, Shanghai Municipality, China
Chaobo Liu, Shanghai Pudong Hospital, Shanghai, 200032, Shanghai Municipality, China
Yanbing Song, Shanghai Pudong Hospital, Shanghai, 200032, Shanghai Municipality, China
Hao Xu, Shanghai Pudong Hospital, Shanghai, 200032, Shanghai Municipality, China
Jin Xing, Shanghai Pudong Hospital, Shanghai, 200032, Shanghai Municipality, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.